← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
176	176 Sana Biotechnology SANA $695M	–	–	–	–
177	SCPS 177 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
178	SCTX 178 Scribe Therapeutics Inc SCTX $378M	–	–	–	–
179	SGTX 179 DELISTED Sigilon Therapeutics, Inc. Common Stock SGTX	–	–	–	–
180	SLBT 180 SL Science Holding Ltd SLBT $864M	–	–	–	–
181	181 Silence Therapeutics SLN $546M	–	–	–	–
182	182 Senti Biosciences Holdings SNTI $6.86M	–	–	–	–
183	183 SOPHiA GENETICS SOPH $593M	–	–	–	–
184	SQZ 184 DELISTED SQZ Biotechnologies Company SQZ	–	–	–	–
185	185 Stoke Therapeutics STOK $1.56B	–	–	–	–
186	186 DELISTED Telesis Bio, Inc. Common Stock TBIO	–	–	–	–
187	TCBP 187 DELISTED TC BioPharm (Holdings) plc American Depositary Shares TCBP	–	–	–	–
188	TCRR 188 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	–	–	–	–
189	189 TScan Therapeutics TCRX $16M	–	–	–	–
190	190 Instil Bio TIL $41.8M	–	–	–	–
191	191 Tenaya Therapeutics TNYA $88.3M	–	–	–	–
192	192 DELISTED Turnstone Biologics TSBX	–	–	–	–
193	193 Taysha Gene Therapies TSHA $1.18B	–	–	–	–
194	194 DELISTED 2seventy bio TSVT	–	–	–	–
195	195 Twist Bioscience TWST $8.89B	–	–	–	–
196	196 10x Genomics TXG $9.17B	–	–	–	–
197	197 DELISTED Verve Therapeutics VERV	–	–	–	–
198	198 GeneDx Holdings WGS $1.96B	–	–	–	–
199	XDNA 199 DELISTED Strategic Trust Kelly CRISPR & Gene Editing Technology ETF XDNA	–	–	–	–